Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Immunovaccine, Vaxil Enter Cancer Vax-Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Immunovaccine, Vaxil Enter Cancer Vax-Pact

Immunovaccine, Inc. has signed a collaborative research agreement with Vaxil BioTherapeutics to explore the efficacy of Vaxil's cancer antigens in Immunovaccine's DepoVax vaccine enhancement platform.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Immunovaccine, Inc. has signed a collaborative research agreement with Vaxil BioTherapeutics to explore the efficacy of Vaxil’s cancer antigens in Immunovaccine’s DepoVax vaccine enhancement platform.

“Vaxil has an innovative approach for identifying cancer antigens that get presented more efficiently by the MHC molecules. Vaxil’s long peptides are good candidates for formulation in our DepoVax platform making this an interesting research partnership,” said Dr. Marc Mansour, vice president of R&D at Immunovaccine.

“In preclinical studies, the DepoVax delivery platform has a demonstrated ability to enhance vaccines, generating a prolonged immune response. We believe that this could fit well with our products and we look forward to making strong advances together in developing the next generation of cancer therapeutics,” said Dr. Lior Carmon, founder and chief executive officer of Vaxil.

Vaxil, based in Israel, is a developer of novel T-cell synthetic vaccines for both therapeutic and prophylactic use. The company’s lead product, ImMucin, an anti-MUC1 therapeutic cancer vaccine, has received regulatory approval to begin Phase I/II trials in Multiple Myeloma patients.

Immunovaccine Inc., based in Canada, is a clinical stage vaccine development company focused on the commercialization of its DepoVax vaccine delivery technology. The company’s lead cancer vaccine DPX-0907 is in a Phase I trial in the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters